The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

Researchers examined CA-125 levels at diagnosis, defining them as elevated/borderline or negative/normal in 250,749 patients ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

Researchers are warning that men who regularly dodge prostate cancer screening appointments are 45% more likely to die from ...

The cancer antigen (CA)-125 test may miss ovarian cancer in some Black and Native American patients, delaying their treatment ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

Preclinical highlights： EVM14 induced a dose-dependent, antigen-specific immune response in mice and significantly inhibited tumor growth in multiple syngeneic tumor models. As a therapeutic ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...